KR20250093576A - 비-조혈조직에 상재하는 γδ Ｔ 세포의 증식 및 이들 세포의 용도 - Google Patents

비-조혈조직에 상재하는 γδ Ｔ 세포의 증식 및 이들 세포의 용도 Download PDF

Info

Publication number
KR20250093576A
KR20250093576A KR1020257019399A KR20257019399A KR20250093576A KR 20250093576 A KR20250093576 A KR 20250093576A KR 1020257019399 A KR1020257019399 A KR 1020257019399A KR 20257019399 A KR20257019399 A KR 20257019399A KR 20250093576 A KR20250093576 A KR 20250093576A
Authority
KR
South Korea
Prior art keywords
cells
cell
hematopoietic
population
article
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257019399A
Other languages
English (en)
Korean (ko)
Inventor
아드리안 헤이데이
올리버 누스바우머
리차드 울프
Original Assignee
캔써 리서치 테크놀로지 리미티드
킹즈 컬리지 런던
더 프란시스 크릭 인스티튜트 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1519198.4A external-priority patent/GB201519198D0/en
Priority claimed from GBGB1612731.8A external-priority patent/GB201612731D0/en
Application filed by 캔써 리서치 테크놀로지 리미티드, 킹즈 컬리지 런던, 더 프란시스 크릭 인스티튜트 리미티드 filed Critical 캔써 리서치 테크놀로지 리미티드
Publication of KR20250093576A publication Critical patent/KR20250093576A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
KR1020257019399A 2015-10-30 2016-10-31 비-조혈조직에 상재하는 γδ Ｔ 세포의 증식 및 이들 세포의 용도 Pending KR20250093576A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB1519198.4 2015-10-30
GBGB1519198.4A GB201519198D0 (en) 2015-10-30 2015-10-30 Expansion of gamma delta t cells resident in non-haematopoietic tissue and uses of these cells
GB1612731.8 2016-07-22
GBGB1612731.8A GB201612731D0 (en) 2016-07-22 2016-07-22 Expansion of non-haematopoietic tissue-resident gamma delta t cells and uses of these cells
KR1020187015244A KR102821381B1 (ko) 2015-10-30 2016-10-31 비-조혈조직에 상재하는 γδ Ｔ 세포의 증식 및 이들 세포의 용도
PCT/EP2016/076264 WO2017072367A1 (en) 2015-10-30 2016-10-31 EXPANSION OF NON-HAEMATOPOIETIC TISSUE-RESIDENT γδ T CELLS AND USES OF THESE CELLS

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187015244A Division KR102821381B1 (ko) 2015-10-30 2016-10-31 비-조혈조직에 상재하는 γδ Ｔ 세포의 증식 및 이들 세포의 용도

Publications (1)

Publication Number Publication Date
KR20250093576A true KR20250093576A (ko) 2025-06-24

Family

ID=57211532

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020257019399A Pending KR20250093576A (ko) 2015-10-30 2016-10-31 비-조혈조직에 상재하는 γδ Ｔ 세포의 증식 및 이들 세포의 용도
KR1020187015244A Active KR102821381B1 (ko) 2015-10-30 2016-10-31 비-조혈조직에 상재하는 γδ Ｔ 세포의 증식 및 이들 세포의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187015244A Active KR102821381B1 (ko) 2015-10-30 2016-10-31 비-조혈조직에 상재하는 γδ Ｔ 세포의 증식 및 이들 세포의 용도

Country Status (16)

Country Link
US (2) US11618885B2 (enExample)
EP (2) EP3368658B1 (enExample)
JP (3) JP2018533373A (enExample)
KR (2) KR20250093576A (enExample)
CN (1) CN108473958A (enExample)
AU (2) AU2016344779B2 (enExample)
CA (1) CA3003077A1 (enExample)
DK (1) DK3368658T3 (enExample)
ES (1) ES2925261T3 (enExample)
IL (3) IL295838B2 (enExample)
MX (2) MX2018005207A (enExample)
MY (1) MY198084A (enExample)
PH (1) PH12018500926A1 (enExample)
PL (1) PL3368658T3 (enExample)
PT (1) PT3368658T (enExample)
WO (1) WO2017072367A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201707048D0 (en) 2017-05-03 2017-06-14 King S College London Expansion of gamma delta cells, compositions, and methods of use thereof
WO2018229163A1 (en) 2017-06-14 2018-12-20 King's College London Methods of activating v delta 2 negative gamma delta t cells
EP3681996B1 (en) 2017-09-15 2024-08-07 King's College London Compositions and methods for enhancing gamma delta t cells in the gut
CN109777778B (zh) * 2017-11-14 2023-07-18 中国科学院广州生物医药与健康研究院 一种基因改造的γδT细胞
GB201804701D0 (en) 2018-03-23 2018-05-09 Gammadelta Therapeutics Ltd Lymphocytes expressing heterologous targeting constructs
WO2020027193A1 (ja) * 2018-07-31 2020-02-06 国立大学法人三重大学 γδ型Ｔ細胞への遺伝子導入方法
GB201818243D0 (en) 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells
CN113423820A (zh) * 2018-11-08 2021-09-21 伽马三角洲疗法有限公司 分离和扩增细胞的方法
PH12021551475A1 (en) 2019-01-07 2022-05-02 Shattuck Labs Inc Heterodimeric proteins for modulating gamma delta t cells
US11098093B2 (en) 2019-01-07 2021-08-24 Shattuck Labs, Inc. Heterodimeric proteins for modulating gamma delta T cells
CN112029719B (zh) * 2019-06-04 2024-05-03 北京医明佳和生物科技有限公司 纯化的双阴性t细胞及其制备和应用
WO2021016652A1 (en) * 2019-07-29 2021-02-04 The University Of Melbourne METHODS AND COMPOSITIONS FOR MONITORING, TREATING AND PREVENTING CMV INFECTION OR GRAFT REJECTION USING γδ T-CELLS
JP2022545196A (ja) 2019-08-16 2022-10-26 ガンマデルタ セラピューティクス リミテッド 抗ｔｃｒデルタ可変１抗体の治療的使用
JP7764364B2 (ja) 2019-08-16 2025-11-05 ガンマデルタ セラピューティクス リミティッド エクスビボγδ Ｔ細胞集団
CN115151565A (zh) 2019-10-31 2022-10-04 莫佛塞斯公司 包含抗CD19抗体和γδT细胞的抗肿瘤组合疗法
EP4114415A1 (en) 2020-03-06 2023-01-11 Sorrento Therapeutics, Inc. Innate immunity killer cells targeting psma positive tumor cells
KR20230013022A (ko) 2020-03-20 2023-01-26 감마델타 테라퓨틱스 엘티디 골수성 악성종양의 치료를 위한 v 델타1+ t 세포
GB202006989D0 (en) * 2020-05-12 2020-06-24 Gammadelta Therapeutics Ltd Methods for isolating gamma delta t cells
PL4269444T3 (pl) 2020-08-14 2025-01-13 GammaDelta Therapeutics Limited Wieloswoiste przeciwciała anty-tcr zmienne delta 1
GB202013962D0 (en) 2020-09-04 2020-10-21 Gammadelta Therapeutics Ltd Immunotherapy composition
AU2022224391A1 (en) 2021-02-17 2023-08-24 Gammadelta Therapeutics Ltd Anti-tcr delta variable 1 antibodies
GB202105113D0 (en) 2021-04-09 2021-05-26 Gammadelta Therapeutics Ltd Novel method
CA3228168A1 (en) 2021-08-03 2023-02-09 Gammadelta Therapeutics Ltd Engineering of gamma delta t cells and compositions thereof
WO2023053994A1 (ja) * 2021-09-29 2023-04-06 アイ ピース， インコーポレイテッド 幹細胞の製造方法
CA3208653A1 (en) 2022-02-17 2022-08-25 Mihriban Tuna Multispecific anti-tcr delta variable 1 antibodies
JPWO2023176896A1 (enExample) * 2022-03-18 2023-09-21
EP4504247A1 (en) 2022-04-04 2025-02-12 Gammadelta Therapeutics Ltd Novel gene armoring
WO2024209429A1 (en) 2023-04-07 2024-10-10 Takeda Pharmaceutical Company Limited T cells for use in treating relapsed or refractory acute myeloid leukemia
CN121532496A (zh) 2023-07-20 2026-02-13 武田药品工业株式会社 用于制备γδT细胞的无网格方法
CN118165933B (zh) * 2024-05-14 2024-07-16 成都美杰赛尔生物科技有限公司 组合物、提高cd39-cd69-t细胞比例的方法
WO2026013159A1 (en) 2024-07-10 2026-01-15 Cytospire Therapeutics Limited Antibodies binding to constant domains of gamma delta t-cell receptors
WO2026013158A1 (en) 2024-07-10 2026-01-15 Cytospire Therapeutics Limited Antibodies binding to constant domains of gamma delta t-cell receptors
CN118853566B (zh) * 2024-09-26 2025-05-09 青岛华赛伯曼医学细胞生物有限公司 一种肿瘤浸润淋巴细胞的培养方法及培养基

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE421573T1 (de) 1998-11-04 2009-02-15 Therapure Biopharma Inc Verfahren zur herstellung von gamma delta t zellen
US20060246520A1 (en) * 2003-05-23 2006-11-02 Institut National De La Sante Et De La Recherche Medicale Gamma delta t cell-mediated therapy
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
WO2009131730A2 (en) * 2008-01-31 2009-10-29 University Of Iowa Research Foundation IMMUNOGENIC COMPOSITIONS FOR ACTIVATING γδ T CELLS
CA2860170C (en) 2010-12-22 2022-06-14 The Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
PT2710123T (pt) * 2011-05-19 2017-10-13 Inst De Medicina Molecular Linha celular de linfócitos compreendendo células t gama-delta, método de composição e produção resultante dos mesmos
EP3060059A4 (en) 2013-10-25 2017-11-01 Board of Regents, The University of Texas System Polyclonal gamma delta t cells for immunotherapy
RU2739770C2 (ru) * 2014-06-11 2020-12-28 полибайосепт ГмбХ Экспансия лимфоцитов с использованием композиции цитокинов для активной клеточной иммунотерапии
CN104293734B (zh) * 2014-09-28 2018-01-09 上海云舜生物技术有限公司 一种人γδT细胞的制备方法
CN104711224A (zh) * 2015-01-09 2015-06-17 天津大学 一种提高人Vδ2T细胞扩增效率的体外培养方法及应用
AU2016274633B2 (en) * 2015-06-09 2022-04-21 Gammadelta Therapeutics Ltd Methods for the production of TCR gamma delta+ T cells
WO2016198906A1 (fr) * 2015-06-10 2016-12-15 Arcelormittal Acier a haute résistance et procédé de fabrication

Also Published As

Publication number Publication date
ES2925261T3 (es) 2022-10-14
US20180312808A1 (en) 2018-11-01
JP2018533373A (ja) 2018-11-15
PH12018500926A1 (en) 2018-11-05
IL295838A (en) 2022-10-01
US20230099491A1 (en) 2023-03-30
EP4148124A1 (en) 2023-03-15
MX2018005207A (es) 2018-09-19
AU2016344779A1 (en) 2018-06-14
HK1253954A1 (en) 2019-07-05
CN108473958A (zh) 2018-08-31
US11618885B2 (en) 2023-04-04
MX2022011003A (es) 2022-10-07
WO2017072367A1 (en) 2017-05-04
IL315329A (en) 2024-10-01
IL295838B2 (en) 2025-02-01
IL258985B2 (en) 2023-02-01
KR20180098235A (ko) 2018-09-03
RU2018119684A3 (enExample) 2020-03-17
KR102821381B1 (ko) 2025-06-13
JP2024069306A (ja) 2024-05-21
JP7451468B2 (ja) 2024-03-18
EP3368658B1 (en) 2022-07-06
EP3368658A1 (en) 2018-09-05
PL3368658T3 (pl) 2022-11-28
CA3003077A1 (en) 2017-05-04
DK3368658T3 (da) 2022-08-01
AU2022283768A1 (en) 2023-02-02
MY198084A (en) 2023-07-31
RU2018119684A (ru) 2019-12-02
IL258985B (en) 2022-10-01
IL295838B1 (en) 2024-10-01
BR112018008293A2 (en) 2018-10-30
PT3368658T (pt) 2022-08-17
JP2022002517A (ja) 2022-01-11
AU2016344779B2 (en) 2023-01-05
IL258985A (en) 2018-06-28

Similar Documents

Publication Publication Date Title
KR102821381B1 (ko) 비-조혈조직에 상재하는 γδ Ｔ 세포의 증식 및 이들 세포의 용도
JP7698672B2 (ja) ガンマデルタｔ細胞の増幅、組成物およびその使用
HK40090397A (en) Expansion of non-haematopoietic tissue-resident gamma delta t cells and uses of these cells
RU2784566C2 (ru) РАЗМНОЖЕНИЕ И ПРИМЕНЕНИЕ НЕГЕМОПОЭТИЧЕСКИХ ТКАНЕРЕЗИДЕНТНЫХ γδ Т-КЛЕТОК
HK1253954B (en) Expansion of non-haematopoietic tissue-resident gamma delta t cells and uses of these cells
EA049808B1 (ru) ЭКСПАНСИЯ γΔ-Т-КЛЕТОК, КОМПОЗИЦИИ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
BR112018008293B1 (pt) Método in vitro para a expansão de células t gama delta não hematopoiéticas
EA044224B1 (ru) ЭКСПАНСИЯ γδ-T-КЛЕТОК, КОМПОЗИЦИИ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
BR122025001918A2 (pt) Métodos de expansão de células t gama delta, composições, seu uso e uso de células t gama delta expandidas

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000